Background Although many patients with venous thromboembolism require extended
treatment, it is uncertain whether it is better to use full-or lower-intensity anticoagulation …

Background Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose
regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without …

Background Standard treatment for venous thromboembolism (VTE) consists of a heparin
combined with vitamin K antagonists. Direct oral anticoagulants have been investigated for …

Abstract Background The global EINSTEIN DVT and PE studies compared rivaroxaban (15
mg twice daily for 3 weeks followed by 20 mg once daily) with enoxaparin/vitamin K …

The optimal duration of anticoagulation for venous thromboembolism (VTE) is uncertain. In
this prespecified analysis, we used data from 2 randomized trials, which compared once …

Background A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been
shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein …

Background Apixaban and rivaroxaban, both direct-acting oral anticoagulants, are being
increasingly used in routine clinical practice because of their fixed dosing and favourable …

Abstract Objective: The phase III EINSTEIN DVT and EINSTEIN PE trials demonstrated the
potential of oral rivaroxaban for the treatment of deep vein thrombosis (DVT) and pulmonary …

Over recent years, research on anticoagulant drugs has been guided by the requirement for
convenient administration and a wide therapeutic window to allow fixed dosing without the …

Venous thromboembolism (VTE) is a common disease associated with high risk for
recurrences, death, and late sequelae, accounting for substantial health care costs …